Background: Excessive gestational weight gain is associated with postpartum weight retention and downstream child obesity. Dopamine plays a critical role in the regulation of energy intake and body weight. The purpose of this study was to examine the relationship between excessive gestational weight gain and dopamine pathway-related polymorphisms, namely the variable nucleotide tandem repeat in the 3′ untranslated region (UTR) region of the SLC6A3 (DAT-1) dopamine transporter gene and the 30-base pair variable nucleotide tandem repeat polymorphism of the 5′ UTR of the monoamine oxidase-A (MAO-A) gene.

Methods: Ninety-three women of mean age 31.7 ± 4.2 years were recruited from the Ottawa and Kingston birth cohort and assessed at 12–20 weeks’ gestation. Mean body mass index was 22.7 ± 2.5 kg/m². Excessive gestational weight gain was defined according to the 2009 Institute of Medicine guidelines based on body mass index. Genotype analyses were performed using polymerase chain reaction and agarose gel electrophoresis.

Results: There was no relationship between the prevalence or magnitude of excessive gestational weight gain among women with the 3′ UTR single nucleotide polymorphism of the DAT-1 gene. However, 70% (19 of 27) of women carrying the MAO-A 4/4 (high activity) allele exceeded recommendations for gestational weight gain compared with 48% (32 of 60) of those with the pooled 3/3, 3/4, or 3/3.5 (low activity) alleles (P, 0.05).

Similarly, those with the MAO-A 4/4 allele had significantly greater gestational weight gain than those with the 3/3, 3/4, or 3/3.5 pooled genotypes (19.3 ± 4.1 versus 17.0 ± 5.0 kg, P = 0.03).

Conclusion: Carriers of the 4/4 variants of the MAO-A gene may be at increased risk for excessive gestational weight gain.

Keywords: gestational weight gain, dopamine genes, monoamine oxidase-A

Introduction

The prevalence of overweight and obesity in children and adults in the US is quickly approaching an epidemic. This represents a serious public health concern given the adverse medical and psychosocial comorbidity of obesity in youth and adults. Pregnancy is considered a critical period for development of obesity in both mother and child, given that excessive gestational weight gain is associated with postpartum weight retention and maternal obesity after birth. Gestational weight gain is independently associated with a higher infant birth weight and a higher prevalence of downstream overweight and obesity in later childhood and beyond. In addition, there is growing evidence to suggest that meeting the Institute of Medicine’s guidelines for gestational weight gain has a beneficial effect on downstream child obesity via minimizing high...
Dopamine is a neurotransmitter that regulates our capacity to feel pleasure, including the motivation to obtain the rewarding properties of palatable food and food intake, in part through the mesolimbic dopaminergic system. The dopamine transporter gene \( \text{DAT-1} \) codes for a dopamine transporter protein (DAT) that is responsible for the reuptake of dopamine released into presynaptic terminals, thereby reducing the availability and level of dopamine at receptor sites. In particular, DAT is highly expressed in the human striatum (an integral part of the mesolimbic reward pathway) where it is a critical regulator of synaptic dopamine. The \( \text{DAT-1} \) gene contains a variable number tandem repeat (VNTR) polymorphism in the 3′ region, and most humans carry the 9-repeat and 10-repeat forms. Although not conclusive, there is strong evidence to suggest that the DAT protein binding site density is elevated approximately 50% in carriers of the 10-repeat VNTR over that of the 9-repeat allele, which could result in lower levels of postsynaptic dopamine as a result of heightened transportation and reuptake of dopamine back to the cell. Because dopamine is an important regulator of feeding, dopamine polymorphisms that alter postsynaptic dopamine availability may impact the rewarding value of food and food intake, consequently influencing energy balance.

Monoamine oxidase (MAO) is a mitochondrial enzyme involved in degrading biological amines, including dopamine, and thereby deaminates dopamine that has been taken back up into the synapse by the dopamine transporter, \( \text{DAT-1} \). MAO-\( A \), another gene in the dopamine pathway, was selected for this study because its promoter region contains a VNTR that influences gene transcription, it is considered to be a precursor of dopamine activity, and it is known to affect levels of dopamine availability. Deckert et al identified four common alleles, ie, the 3, 3.5, 4, and 5 30-base pair repeats, with the most common alleles being the 3-repeats and 4-repeats. The 4-repeat alleles have been associated with more efficient transcription than the 3-repeat alleles, and so could be considered to be “highly active” alleles and have been shown to be associated with increased dopamine availability.

To our knowledge, no study to date has examined the relationship between polymorphisms in the dopamine transporter gene (\( \text{DAT-1} \)) or MAO-\( A \) gene, and gestational weight gain. Therefore, the purpose of this study was to assess the relationship between two dopamine pathway gene polymorphisms, ie, the dopamine transporter (\( \text{DAT-1} 9/9, 9/10 \) versus \( 10/10 \) alleles) and the MAO-\( A \) (3/3, 3/4, 3.5/3 versus 4/4, 4/5 alleles), and gestational weight gain. Among the many reported polymorphisms reported for the dopamine metabolism genes, we have selected these because they are located in the regulatory regions (\( 5′ \text{UTR}/3′ \text{UTR} \)) of the gene.

**Materials and methods**

**Participants**

Ninety-three women of mean age 31.7 ± 4.2 years from the Ottawa and Kingston birth cohort were assessed at 12–20 weeks’ gestation. Mean prepregnancy body mass index was 22.7 ± 2.5 kg/m\(^2\). Over 80% of the sample was Caucasian and virtually all had some post-secondary education, so the sample was relatively homogeneous and representative of a middle-to-high socioeconomic status demographic. Excessive gestational weight gain was defined according to the most recent 2009 Institute of Medicine guidelines on weight gain during pregnancy, which are based on prepregnancy body mass index. More specifically, the Institute of Medicine guidelines indicate that women who are classified as underweight based on a prepregnancy body mass index <18.5 should gain 12.5–18 kg (28–40 lb) during gestation. Women classified as normal weight based on a prepregnancy body mass index of 18.5–24.9 should gain 11.5–16 kg (25–35 lb). Women classified as overweight based on a body mass index of 25–29.9 should gain 7–11.5 kg (15–25 lb), while women classified as obese based on a prepregnancy body mass index of ≥30 should gain 5–9 kg (11–20 lb). Total gestational weight gain was assessed by subtracting the initial self-reported prepregnancy weight from the final measured weight at delivery. Women from the Ottawa and Kingston birth cohort who exceeded gestational weight gain guidelines were compared with age-matched Ottawa and Kingston participants who met the guidelines. Exclusion criteria were smoking during pregnancy, medical conditions that could influence weight gain, such as prepregnancy or gestational diabetes, hypothyroidism, hyperthyroidism, Cushing’s disease, inflammatory bowel disease, or celiac disease, as evaluated by a physician or registered nurse by interview or examination. Women who were taking medications that could affect their body composition and
weight gain throughout gestation were also excluded. Women meeting the inclusion criteria and who gave informed consent for their blood/DNA samples to be used were selected. This resulted in a sample of 43 women who met the gestational weight gain recommendations during pregnancy and 50 being categorized as excessive weight gainers.

Informed written consent from each participant was obtained in accordance with the principles expressed in the Declaration of Helsinki guidelines for human subjects. The study was reviewed and approved by the research ethics boards of the Children’s Hospital of Eastern Ontario and The Ottawa Hospital.

**Procedures**

Genomic DNA was extracted from whole blood using standard phenol extraction methods and purified using a FlexiGene DNA extraction kit (Qiagen, Valencia, CA). The VNTR polymorphism of the DAT-1 gene was amplified from the genomic DNA using polymerase chain reaction (PCR) with primers (Invitrogen, Carlsbad, CA) designed by Vandenbergh et al. The PCR was performed in a total volume of 27.5 μL using 100 ng of genomic DNA. The PCR mix included 2 μL of 2.5 mM dNTPs, 1.0 μL each of 10 mM forward and reverse primers, 5 μL of PCR buffer (Qiagen), 5 μL Q solution (Qiagen), and 0.25 μL 5U Taq polymerase. The PCR conditions were optimized using a thermal cycler (GeneAmp PCR system 9700, Applied Biosystems, Foster City, CA) as follows: initial denaturation at 94°C for four minutes, followed by 30 cycles at 94°C for one minute, 60°C for one minute, and 72°C for one minute, with a final extension of five minutes at 72°C. The PCR products were separated by electrophoresis using a 2% agarose gel and stained with ethidium bromide. Similarly the MAO-A VNTR polymorphism was identified in an identical manner using primers designed by Jonsson et al.

Gels were then visualized under ultraviolet light and photographed using a Vilbert Lourmat system, and images were printed on a video graphic printer (UP-895MD, Sony Corporation, Tokyo, Japan) using both positive and negative contrast. Images of the gels were scanned at high resolution using an HPscanjet 8200 scanner, and were then genotyped visually by comparison with a molecular weight standard (GeneRuler) and the known amplification size of the PCR products.

**Statistical analysis**

Descriptive analyses comparing “normal” versus “excessive” weight gainers on age, prepregnancy weight and body mass index, and absolute weight gain were conducted using independent t-tests. Classification of the dopamine transporter (DAT-1) polymorphism first involved coding the alleles as 9/9 (n = 8) and 9/10 (n = 24) or 10/10 (n = 60) allele patterns. The one participant who had an allele pattern other than the 9/9, 9/10, or 10/10 was dropped from the analysis. Analyses were performed combining the 9/9 and 9/10 allele patterns together versus the 10/10 allele pattern, thus comparing the participants for the presence or absence of the 9 allele genotype. Chi-square analyses were conducted to compare the prevalence of these dopamine allele patterns for “normal” versus “excessive” gestational weight gainers. Independent t-tests were also used to compare the amount of gestational weight gain by dopamine allele patterns.

The MAO-A allele pattern was categorized as 3/3 (n = 18), 3/4 (n = 42), 4/4 (n = 27), or 3/3.5 (n = 2). Chi-square analyses were done to compare the prevalence of MAO-A alleles (3/3 + 3/4 + 3/3.5 versus 4/4) between “normal” and “excessive” weight gainers. Independent t-tests were also used to compare the amount of gestational weight gain according to MAO-A allele patterns.

Multiple regression analyses were conducted to ascertain the independent and interactive effects of the DAT-1 and MAO-A “at risk” allele patterns on the amount of gestational weight gain controlling for prepregnancy, body mass index, and age. All analyses were done using Statistical Package for Social Sciences version 19 software (SPSS Inc, Chicago, IL) with alpha preset at 0.05.

**Results**

The mean age of the patients was 31.7 ± 4.2 years. Excessive and normal weight gainers did not differ significantly in age, but excessive gainers had a greater median (interquartile range) prepregnancy weight (64.0 [57.0, 68.0] kg versus 59.0 [54.0, 63.0] kg, P < 0.01), body mass index (23.4 [21.4, 26.0] versus 21.5 [20.3, 23.2], P < 0.01), and amount of weight gain throughout gestation (20.0 [18.8, 23.0] kg versus 13.6 [12.2, 15.0] kg, P < 0.001), as selected for in the initial selection of the sample.

Regarding DAT-1, Table 1 shows the percentage of each genotype observed for the sample. Chi-square analyses examining the pooled 9/9 and 9/10 versus the 10/10 genotypes revealed no significant differences in the distribution of DAT-1 polymorphisms between normal and excessive gestational weight gainers (χ² = 0.00, P = 1.00). More specifically, 53% (17 of 32) of the excessive weight gainers had the 9/9 or 9/10 genotype, while 53% (32 of 60) had the 10/10 allele. Similarly, t-tests revealed no differences...
in gestational weight gain between individuals possessing the 9/9 or 9/10 genotypes and those with the 10/10 genotype (17.5 ± 4.7 kg versus 17.5 ± 4.9 kg; t = [1.90] = −0.02, P = 0.98).

Regarding MAO-A, Table 1 shows the distribution of VNTR genotypes in the sample Chi-square analyses examining the pooled 3/3, 3/4, and 3/3.5 genotype versus the 4/4 genotype revealed a significant difference in the distribution of the MAO-A polymorphisms between normal and excessive gestational weight gainers (χ² = 4.9, P = 0.04). More specifically, 70% (19 of 27) of individuals with the 4/4 MAO-A genotype were excessive weight gainers compared with only 48% (30 of 62) of those with the pooled 3/3, 3/4, and 3/3.5 genotypes. Similarly, t-tests revealed that those with the 4/4 genotype had significantly greater gestational weight gain than those with the pooled 3/3, 3/4, 3/3.5 genotypes (19.3 ± 4.1 kg versus 17.0 ± 5.0 kg; t = [1.87] = −2.192, P = 0.03). Multiple regression analyses indicated that this significant relationship was maintained after controlling for prepregnancy body mass index and age (beta = 0.20, R² = 0.14, P = 0.006). The MAO-A by DAT-1 interaction effect on gestational weight gain was not significant.

Table 1 Characteristics of study sample stratified by gestational weight gain

<table>
<thead>
<tr>
<th>Variables</th>
<th>Median (IQR)</th>
<th>Normal (n = 43)</th>
<th>Excessive (n = 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)*</td>
<td></td>
<td>21.5 (20.3, 23.2)</td>
<td>23.4 (21.4, 26.0)</td>
</tr>
<tr>
<td>Body weight (kg)*</td>
<td></td>
<td>59.0 (54.0, 63.0)</td>
<td>64.0 (57.0, 68.0)</td>
</tr>
<tr>
<td>Gestational weight gain (kg)**</td>
<td></td>
<td>13.6 (12.2, 15.0)</td>
<td>20.0 (18.8, 23.0)</td>
</tr>
<tr>
<td>Genes</td>
<td>Genotype</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>DAT-1</td>
<td>9/9</td>
<td>1 (12.5)</td>
<td>7 (87.5)</td>
</tr>
<tr>
<td></td>
<td>9/10</td>
<td>14 (58)</td>
<td>10 (42)</td>
</tr>
<tr>
<td></td>
<td>10/10</td>
<td>28 (47)</td>
<td>32 (53)</td>
</tr>
<tr>
<td>MAO-A</td>
<td>3/3</td>
<td>10 (56)</td>
<td>8 (44)</td>
</tr>
<tr>
<td></td>
<td>3/4</td>
<td>22 (52)</td>
<td>20 (48)</td>
</tr>
<tr>
<td></td>
<td>3/3.5</td>
<td>0 (0)</td>
<td>2 (100)</td>
</tr>
<tr>
<td></td>
<td>4/4</td>
<td>8 (30)</td>
<td>19 (70)</td>
</tr>
</tbody>
</table>

Notes: *P < 0.01; **P < 0.001. Abbreviation: IQR, interquartile range.

Discussion

To the best of our knowledge, this is the first study to examine whether the allele patterns associated with altered dopamine availability from selective polymorphisms of the dopamine transporter (DAT-1) and MAO-A genes would be associated with excessive gestational weight gain. There was no significant difference in prevalence of excessive gestational weight gain or magnitude of weight gain between the DAT-1 3’-40-base pair VNTR 9/9 and 9/10 genotypes compared with the 10/10 genotypes, although there was a trend toward more prevalent gestational weight gain among carriers of the 9/9 genotype (ie, seven of eight women), an effect that may have reached significance if the sample was larger. However, women with the MAO-A promoter region VNTR allele pattern associated with increased dopamine activity (ie, the 4/4 genotype) gained significantly more weight during pregnancy than those with genotypes associated with “low activity” or reduced dopamine function (ie, pooled 3/3, 3/4, and 3/3.5 alleles). This relationship also remained significant after controlling for prepregnancy body mass index and age. In addition, a higher prevalence of women (70%) having the allele pattern associated with increased dopamine activity (ie, 4/4) were classified as excessive weight gainers compared with 48% of subjects having the allele pattern associated with reduced dopamine function (pooled 3/3, 3/4, or 3/3.5 genotypes).

When interpreting our findings, it is important to note there are two different conceptualizations of how dopamine relates to feeding behavior, energy balance, and obesity. One paradigm suggests that those with higher available levels of dopamine, which mediates the rewarding value of food and other appetitive behaviors, tend to have a heightened sensitivity to reward, a greater hedonic capacity, and a stronger motivation to consume palatable foods that often results in overeating and obesity. This paradigm also suggests that a sluggish dopaminergic system with low availability of dopamine is associated with an anhedonic demeanor and a relative insensitivity to reward. Our results reflecting a significant relationship between the high active MAO-A (4/4) allele and gestational weight gain are consistent with this conceptualization. In addition, the highly active 4-repeat allele has been shown to be associated with greater rates of cigarette smoking, which is also consistent with this conceptualization. Although we did not find a relationship between DAT-1 and prevalence or magnitude of excessive gestational weight gain, other studies have found the 9-repeat alleles of DAT-1 were more prevalent among those with binge eating disorder. Additional evidence for this conceptualization comes from studies showing the DAT-1 gene moderates the response to a dopamine agonist whereby those with the 9-repeat alleles show greater reductions in appetite ratings and food intake.

A competing conceptualization of how appetitive behaviors such as eating and substance abuse relate to...
Dopamine availability is known as the reward deficiency syndrome, which is steadily growing in empirical support. The reward deficiency syndrome proposed by Blum et al. and Noble et al. was initially based on addiction research and more recently applied to obesity. This theory posits that increased drive to eat excessively leading to obesity has its roots in low levels of brain dopamine and these increased appetite behaviors are methods of “self-medicating” to boost dopamine levels and compensate for a deficiency in the reward or pleasure one experiences. Although our current findings are not consistent with this theory, several studies have found that the DAT-1 10-repeat allele, which is associated with reduced dopamine availability via overactive transport, is associated with greater food intake and risk of obesity compared with those having the 9/9 or 9/10 repeat alleles. Stronger evidence for the reward deficiency syndrome comes from a series of large studies that found that the MAO-A 3 repeat alleles, which are considered to be low-active with less dopamine availability, was associated with obesity in individuals and families and increased body mass index in men but not women. It is also important to note that two large epidemiological studies from the US did not find an association between the MAO-A gene and body mass index, change in body mass index over time, or food intake. These inconsistent findings highlight the complexity of the gene-environment interaction, indicating that more research is needed to determine the role these dopamine gene variants play in energy intake, the reinforcing value of food, body weight, and weight gain among various populations.

Strengths and limitations

The strengths of this study include a novel research question, as well as using prepregnancy body mass index as a covariate given that overweight women are at increased risk of exceeding gestational weight gain guidelines. Several limitations also need to be acknowledged. First, given that this is the first study of its kind and included a relatively small sample size, its findings should be interpreted with caution because replication studies are needed. Moreover, due to resource limitations, we focused on two candidate genes in the dopamine pathway. However, we acknowledge that other polymorphic variants that influence dopamine function, such as various dopamine receptors (DRD2 and DRD4) and enzymes (COMT and MAO-B) have been shown to be associated with increased food reinforcement and intake, weight gain, and obesity and should be considered in future studies examining the influence of dopamine genes and gestational weight gain. In addition, our sample was quite homogeneous in that almost all women were Caucasian and had completed post-secondary education, so it is unclear how our findings would generalize to pregnant women of lower socioeconomic status or different race or ethnicity. Finally, given that some studies have shown an association between polymorphisms that alter the availability of synapic dopamine and sensitivity to food reward and intake, it is assumed the mechanisms linking dopamine pathway polymorphisms and excessive gestational weight gain are mediated through energy intake. However, we did not measure energy intake throughout gestation and this limitation should be addressed in future research.

Conclusion

Although the present findings should be interpreted with caution, our data suggest that women who are carriers of the highly active MAO-A gene variant (4/4 allele), which has been associated with increased post-synaptic dopamine availability, may be at higher risk of gestational weight gain. This is problematic because excessive gestational weight gain may predispose women to several untoward consequences, such as greater weight retention leading to maternal obesity post partum and increased risk of downstream child obesity and cardiometabolic complications. Given the health risks associated with gestational weight gain, it is suggested that this group of pregnant women who carry the high active MAO-A genotype would benefit from being targeted for lifestyle intervention during pregnancy, which a recent systematic review shows can be efficacious in minimizing gestational weight gain. Further studies are needed to replicate these findings in a larger sample, as well as address other aspects of the present study’s limitations.

Acknowledgments

The authors would like to thank all the subjects who participated in the study and all the research staff who assisted with data collection. We would also like to thank Nancy Carson and Barron Gin from the Apoptosis Research Center at the Children’s Hospital of Eastern Ontario for providing us with laboratory space and equipment and for overseeing the genotyping process. At the time the study was conducted, GSG, MW, and ED were supported by new investigator awards from the Canadian Institutes of Health Research. JDC was supported by a University of Ottawa graduate scholarship. ZMF was supported by an Ontario Graduate Scholarship. KBA and GG held a Canadian Foundation of Innovation Award to equip the laboratory at the Children’s Hospital of Eastern Ontario for providing us with laboratory space and equipment and for overseeing the genotyping process. At the time the study was conducted, GSG, MW, and ED were supported by new investigator awards from the Canadian Institutes of Health Research. JDC was supported by a University of Ottawa graduate scholarship. ZMF was supported by an Ontario Graduate Scholarship. KBA and GG held a Canadian Foundation of Innovation Award to equip the laboratory at the Children’s
Hospital of Eastern Ontario Research Institute where the study was conducted.

Disclosure

The authors report no conflicts of interest in this work.

References


